Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:DYN NASDAQ:HRMY NASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$5.10-0.8%$4.40$2.25▼$7.53$493.14M2.171.76 million shs858,868 shsDYNDyne Therapeutics$12.99+1.0%$11.39$6.36▼$37.08$1.83B1.12.18 million shs1.93 million shsHRMYHarmony Biosciences$32.29-0.6%$35.64$26.47▼$41.61$1.87B0.84662,388 shs822,577 shsIMCRImmunocore$33.81-1.8%$34.03$23.15▼$39.33$1.73B0.77269,646 shs174,180 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-1.15%+3.21%+18.98%+14.73%-29.10%DYNDyne Therapeutics-2.21%-3.31%+3.88%+18.42%-62.24%HRMYHarmony Biosciences+0.34%-9.29%-11.85%+0.09%-16.47%IMCRImmunocore-2.33%-6.06%+4.68%+6.37%+2.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$5.10-0.8%$4.40$2.25▼$7.53$493.14M2.171.76 million shs858,868 shsDYNDyne Therapeutics$12.99+1.0%$11.39$6.36▼$37.08$1.83B1.12.18 million shs1.93 million shsHRMYHarmony Biosciences$32.29-0.6%$35.64$26.47▼$41.61$1.87B0.84662,388 shs822,577 shsIMCRImmunocore$33.81-1.8%$34.03$23.15▼$39.33$1.73B0.77269,646 shs174,180 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-1.15%+3.21%+18.98%+14.73%-29.10%DYNDyne Therapeutics-2.21%-3.31%+3.88%+18.42%-62.24%HRMYHarmony Biosciences+0.34%-9.29%-11.85%+0.09%-16.47%IMCRImmunocore-2.33%-6.06%+4.68%+6.37%+2.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 2.86Moderate Buy$16.29219.33% UpsideDYNDyne Therapeutics 3.06Buy$34.07162.25% UpsideHRMYHarmony Biosciences 3.00Buy$51.0057.94% UpsideIMCRImmunocore 2.45Hold$56.8968.26% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, HRMY, DYN, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/25/2025IMCRImmunocoreJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$34.00 ➝ $13.008/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $40.008/1/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.007/29/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.00 ➝ $31.007/29/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $38.007/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/ADYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AHRMYHarmony Biosciences$714.73M2.60$2.93 per share11.03$11.56 per share2.79IMCRImmunocore$310.20M5.49N/AN/A$7.20 per share4.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.840.00N/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)HRMYHarmony Biosciences$145.49M$3.1010.4810.380.3823.44%26.34%17.71%11/4/2025 (Estimated)IMCRImmunocore-$51.09M-$0.400.00N/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)Latest CMPS, HRMY, DYN, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 million7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/A7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.168.828.82DYNDyne Therapeutics0.1716.8316.83HRMYHarmony Biosciences0.203.843.80IMCRImmunocore1.015.895.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%DYNDyne Therapeutics96.68%HRMYHarmony Biosciences86.23%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%DYNDyne Therapeutics20.77%HRMYHarmony Biosciences23.60%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableDYNDyne Therapeutics100142.26 million112.72 millionOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionableCMPS, HRMY, DYN, and IMCR HeadlinesRecent News About These CompaniesImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.89 Consensus PT from AnalystsSeptember 15 at 2:30 AM | americanbankingnews.comAssessing Immunocore Holdings (NasdaqGS:IMCR) Valuation Following Recent Share Price MomentumSeptember 14 at 7:00 PM | finance.yahoo.comImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Hold" by AnalystsSeptember 14 at 2:29 AM | marketbeat.comImmunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCubist Systematic Strategies LLC Trims Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 9, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Downgraded by Zacks Research to "Hold"September 8, 2025 | marketbeat.comBanque Transatlantique SA Invests $278,000 in Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 7, 2025 | marketbeat.comCheckpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 6, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Price Up 7.4% - Should You Buy?September 5, 2025 | marketbeat.comImmunocore to present at upcoming investor conferencesSeptember 4, 2025 | globenewswire.comFrazier Life Sciences Management L.P. Grows Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Purchases 807,338 Shares of Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 4, 2025 | marketbeat.comArmistice Capital LLC Sells 222,000 Shares of Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 2, 2025 | marketbeat.comJefferies Financial Group Initiates Coverage on Immunocore (NASDAQ:IMCR)August 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Buys 351,610 Shares of Immunocore Holdings PLC Sponsored ADR $IMCRAugust 23, 2025 | marketbeat.comImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 19, 2025 | marketbeat.comQ3 Earnings Forecast for Immunocore Issued By HC WainwrightAugust 16, 2025 | marketbeat.comImmunocore’s Earnings Call Highlights Robust Growth and Strategic ExpansionAugust 13, 2025 | msn.comImmunocore Holdings plc (NASDAQ:IMCR) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comImmunocore Holdings plc (IMCR) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comImmunocore Holdings plc 2025 Q2 - Results - Earnings Call PresentationAugust 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, HRMY, DYN, and IMCR Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$5.10 -0.04 (-0.78%) Closing price 04:00 PM EasternExtended Trading$5.11 +0.01 (+0.10%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Dyne Therapeutics NASDAQ:DYN$12.99 +0.13 (+1.01%) Closing price 04:00 PM EasternExtended Trading$12.99 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Harmony Biosciences NASDAQ:HRMY$32.29 -0.21 (-0.65%) Closing price 04:00 PM EasternExtended Trading$32.47 +0.18 (+0.54%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Immunocore NASDAQ:IMCR$33.81 -0.61 (-1.77%) Closing price 04:00 PM EasternExtended Trading$33.85 +0.04 (+0.12%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
